Genomtec S.A. (FRA:4VI)

Germany flag Germany · Delayed Price · Currency is EUR
0.941
-0.004 (-0.42%)
Last updated: Dec 5, 2025, 9:59 AM CET
-32.01%
Market Cap 16.06M
Revenue (ttm) 3.52K
Net Income (ttm) -2.58M
Shares Out n/a
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 21
Open 0.941
Previous Close 0.945
Day's Range 0.941 - 0.941
52-Week Range 0.933 - 2.210
Beta n/a
RSI 30.94
Earnings Date Nov 28, 2025

About Genomtec

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 26
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4VI
Full Company Profile

Financial Performance

In 2024, Genomtec's revenue was 1,000, a change of 0.00% compared to the previous year's 1,000. Losses were -11.21 million, 24.4% more than in 2023.

Financial numbers in PLN Financial Statements

News

There is no news available yet.